Rituximab Therapy for Systemic Rheumatoid Vasculitis: Indications, Outcomes, and Adverse Events.

Caitrin M CoffeyMichael D RichterCynthia S CrowsonMatthew J KosterKenneth J WarringtonSteven R YtterbergAshima Makol

Published in: The Journal of rheumatology (2019)

Systemic RV is difficult to treat effectively. CR of RV was achieved in 62% and PR in 38% of patients within 12 months of RTX use. Further evidence is needed to inform treatment for patients with RV.

Keyphrases

mycobacterium tuberculosis
end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
diffuse large b cell lymphoma
metabolic syndrome
type diabetes
adipose tissue
patient reported outcomes
rheumatoid arthritis
drug induced
hodgkin lymphoma
weight loss